On the other hand, AnxA5 knockdown impeded tumourigenesis in subcutaneous xenografts from renal cell carcinoma [264], with the latter two studies suggesting an involvement of PI3K/Akt signaling and implicating AnxA5 as a potential biomarker in glioma and renal cell carcinoma. This evidence concerns the gene AKT1 and hereditary clear cell renal cell carcinoma.